Nalfon
Nalfon Brand names, Nalfon Analogs
Nalfon Brand Names Mixture
- No information avaliable
Nalfon Chemical_Formula
C24H33N3O4
Nalfon RX_link
No information avaliable
Nalfon fda sheet
Nalfon msds (material safety sheet)
Nalfon Synthesis Reference
No information avaliable
Nalfon Molecular Weight
427.537 g/mol
Nalfon Melting Point
No information avaliable
Nalfon H2O Solubility
Very slightly soluble
Nalfon State
Solid
Nalfon LogP
1.876
Nalfon Dosage Forms
Tablets (extended release - 500 mg)
Nalfon Indication
For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.
Nalfon Pharmacology
Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.
Nalfon Absorption
Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.
Nalfon side effects and Toxicity
In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.
Nalfon Patient Information
AMITIZA™ may cause nausea. If this occurs, concomitant administration of food with AMITIZA™ may reduce symptoms of nausea. AMITIZA™ should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe consult your physician.
Nalfon Organisms Affected
Humans and other mammals
